Literature DB >> 7557023

High-affinity binding of melatonin by human circulating T lymphocytes (CD4+).

M G Gonzalez-Haba1, S Garcia-Mauriño, J R Calvo, R Goberna, J M Guerrero.   

Abstract

This paper shows the presence of high-affinity binding sites for melatonin in human circulating T lymphocytes, but not in B lymphocytes. The binding of melatonin to T cells was dependent on time, stable, reversible, saturable, specific, and inversely correlated to the production of melatonin, expressed as the nocturnal 12 h production of its urinary metabolite 6-sulfatoxymelatonin. The affinity of these binding sites (Kd = 0.27 nM) suggests that they may recognize the physiological concentrations of melatonin in serum. Moreover, among the lymphocyte subpopulations studied, binding of melatonin was mostly found in CD4+ cells rather than in CD8+ cells. Results suggest that CD4+ cells may be the target of melatonin among the human circulating lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7557023     DOI: 10.1096/fasebj.9.13.7557023

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  8 in total

1.  Melatonin provides signal 3 to unprimed CD4(+) T cells but failed to stimulate LPS primed B cells.

Authors:  V Raghavendra; V Singh; A V Shaji; H Vohra; S K Kulkarni; J N Agrewala
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

2.  Melatonin treatment enhances the efficiency of mice immunization with Venezuelan equine encephalomyelitis virus TC-83.

Authors:  B Negrette; E Bonilla; N Valero; H Pons; J Garcia Tamayo; L Chacín-Bonilla; S Medina-Leendertz; F Añez
Journal:  Neurochem Res       Date:  2001-07       Impact factor: 3.996

3.  Prevention of immune dysfunction and vitamin E loss by dehydroepiandrosterone and melatonin supplementation during murine retrovirus infection.

Authors:  Z Zhang; M Araghi-Niknam; B Liang; P Inserra; S K Ardestani; S Jiang; S Chow; R R Watson
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

4.  Radiomitigation by Melatonin in C57BL/6 Mice: Possible Implications as Adjuvant in Radiotherapy and Chemotherapy.

Authors:  Akanchha Mani Tripathi; Shahanshah Khan; Nabo Kumar Chaudhury
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

5.  Immunomodulatory effect of melatonin in SK-LU-1 human lung adenocarcinoma cells co-cultured with peripheral blood mononuclear cells.

Authors:  P Plaimee; M Khamphio; N Weerapreeyakul; S Barusrux; N P Johns
Journal:  Cell Prolif       Date:  2014-07-23       Impact factor: 6.831

6.  Antagonistic effect of luzindole in mice treated with melatonin during the infection with the venezuelan equine encephalomyelitis virus.

Authors:  Nereida Valero; Anaís Nery; Ernesto Bonilla; Luz Marina Espina; Leonor Chacin-Bonilla; Florencio Añez; Mery Maldonado; Eddy Meleán
Journal:  Neurochem Res       Date:  2008-07-02       Impact factor: 3.996

7.  Melatonin, immune function and aging.

Authors:  V Srinivasan; G J M Maestroni; D P Cardinali; A I Esquifino; S R Pandi Perumal; S C Miller
Journal:  Immun Ageing       Date:  2005-11-29       Impact factor: 6.400

8.  Melatonin anticancer effects: review.

Authors:  Giuseppe Di Bella; Fabrizio Mascia; Luciano Gualano; Luigi Di Bella
Journal:  Int J Mol Sci       Date:  2013-01-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.